ASXL1 and acute myeloid leukemia: It is therefore highly plausible that some TET2/ASXL1 co-mutated cases evolved from long-standing, undiagnosed low-blast-count MDS or clonal hematopoiesis of indeterminate potential (CHIP) that rapidly progressed to overt AML before the MDS phase became clinically detectable.